Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07631884 | Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor | not yet recruiting | Phase 2 | 15 | Haihua YuanOTHER | 0 | Jun 8, 2026 | clinicaltrials |
| NCT07504445 | Clinical Study on the Efficacy and Safety of CAR-DC in the Treatment of Advanced Solid Tumors | not yet recruiting | Early Phase 1 | 10 | Peking University Shenzhen HospitalOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07593144 | A Single-Arm, Open-Label Phase Ia/Ib Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of FS-207 in Patients With Advanced Solid Tumors With High Microsatellite Instability (MSI-H) | not yet recruiting | Phase 1 | 156 | Foresight Therapeutics (Hefei) Co., Ltd.INDUSTRY | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07622225 | SYS6006 in Combination With Enlonstobart Injection Versus Enlonstobart Injection in Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 264 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Jun 3, 2026 | clinicaltrials |
| NCT07623707 | A Study of FG-B901 Monotherapy or Combination With Chemotherapy in Advanced or Metastatic Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 264 | FutureGen Biopharmaceutical (Beijing) Co., LtdINDUSTRY | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07624214 | Study of LT-010391 in Participants With KRAS G12D-Mutant Solid Tumors | not yet recruiting | Phase 1 | 198 | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.INDUSTRY | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07624864 | A Study to Evaluate the Safety, Tolerability, PK and Efficacy of Hemay5087 in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 24 | Ganzhou Hemay Pharmaceutical Co., LtdINDUSTRY | 0 | Jun 3, 2026 | clinicaltrials |
| NCT07615660 | Clinical Study of CVL006 Combination With 9MW2821(CVL006-T1003) | not yet recruiting | Phase 1 / Phase 2 | 108 | Convalife (Shanghai) Co., Ltd.INDUSTRY | 0 | May 29, 2026 | clinicaltrials |
| NCT07615894 | WSK-IM02 in Advanced Solid Tumors With Malignant Effusions (Phase I) | not yet recruiting | Phase 1 | 9 | WestVac Biopharma Co., Ltd.INDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT07611370 | Evaluating the Effects of Propionate and Butyrate Supplementation on the Intestinal Health of Healthy Volunteers | not yet recruiting | Phase 1 | 12 | City of Hope Medical CenterOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT07612085 | A Wearable Biosensor Patch for Non-Invasive Monitoring for Patients Undergoing Abdominal or Chest Surgery | not yet recruiting | N/A | 20 | City of Hope Medical CenterOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT07612137 | Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 282 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | May 28, 2026 | clinicaltrials |
| NCT07612488 | A Study of CS231295 in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 42 | ThalassaX Therapeutics United States LtdINDUSTRY | 1 | May 28, 2026 | clinicaltrials |
| NCT07606313 | Phase I Randomized Controlled Trial of Functional Resistance Training in Older Cancer Survivors: The ACES Trial(ACES) | not yet recruiting | N/A | 150 | OHSU Knight Cancer InstituteOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT07596381 | FAK Inhibitor in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 75 | InxMed (Shanghai) Co., Ltd.INDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT07594028 | Phase I/II Study of SCTB41 Plus SCTB39-1with or Without Standard Therapy in Advanced Solid Tumours | not yet recruiting | Phase 1 / Phase 2 | 126 | Sinocelltech Ltd.INDUSTRY | 0 | May 18, 2026 | clinicaltrials |
| NCT07590648 | Early Discontinuation of Antibiotics in Paediatric High-risk Febrile Neutropenia(E-STOP2) | not yet recruiting | Phase 4 | 136 | Hospital Universitari Vall d'Hebron Research InstituteOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT07591285 | A Study of SYS6051 in Subjects With Advanced Solid Tumors | not yet recruiting | Phase 1 | 114 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | May 15, 2026 | clinicaltrials |
| NCT07587879 | Novel mRNA-LNP-Based Intratumoral Immunotherapy in Patients With Advanced Malignant Solid Tumors(mRNA-LNP) | not yet recruiting | Phase 1 / Phase 2 | 60 | IntraAb, Inc.INDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT07582822 | JH021 in Patients With Advanced Solid Tumors or EGFR-Mutant NSCLC | not yet recruiting | Phase 1 | 60 | Biotech Pharmaceutical Co., Ltd.OTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07583771 | A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma | not yet recruiting | Phase 1 | 186 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT07583953 | An Exploratory Study of Personalized Cancer Vaccine in Adjuvant Therapy of Solid Tumors | not yet recruiting | Early Phase 1 | 50 | Suzhou Abogen Biosciences Co., Ltd.INDUSTRY | 0 | May 13, 2026 | clinicaltrials |
| NCT07566247 | A Phase I Clinical Study of AK150 in Advanced Malignant Solid Tumor | not yet recruiting | Phase 1 | 96 | AkesoINDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT07562347 | Clinical Experience and Real-world Safety and Effectiveness of Envafolimab: Patient Access Program(ENCOMPASS STUD) | not yet recruiting | — | 120 | IR INNOVATE RESEARCH PRIVATE LIMITEDINDUSTRY | 0 | May 1, 2026 | clinicaltrials |
| NCT07419581 | A Study of Freeze-Dried Miracle Fruit (MiraBurst) on Participants Receiving Cancer Treatment | not yet recruiting | N/A | 45 | Case Comprehensive Cancer CenterOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07558200 | Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors | not yet recruiting | Phase 1 | 138 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07545486 | Ablative Therapy of Oligometastatic Tumor After Response to Conventional First Line Treatment(ATOM-1st) | not yet recruiting | — | 1,235 | ChirecOTHER | 5 | Apr 22, 2026 | clinicaltrials |
| NCT07542704 | A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies | not yet recruiting | Phase 1 | 48 | Kumquat Biosciences Inc.INDUSTRY | 0 | Apr 21, 2026 | clinicaltrials |
| NCT07540650 | Prophylactic Radiotherapy to Prevent Bone Complications in Patients With Metastatic Solid Cancers(pRevenT) | not yet recruiting | Phase 2 | 90 | Institute of Oncology LjubljanaOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07509684 | A Phase Ib/II Study Evaluating Injectable ALK-N001 in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 190 | Zhejiang Anglikang Pharmaceutical Co., Ltd.INDUSTRY | 0 | Apr 13, 2026 | clinicaltrials |
| NCT07510841 | JY016 Injection in Patients With Advanced Solid Tumors Expressing EGFR | not yet recruiting | Phase 1 / Phase 2 | 228 | Biotech Pharmaceutical Co., Ltd.OTHER | 0 | Apr 6, 2026 | clinicaltrials |
| NCT06781125 | One Trial of JCXH-211 Intratumoral Injection Combined With Anti-PD-1 Antibody in Patients With Malignant Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 72 | Immorna Biotherapeutics, Inc.INDUSTRY | 0 | Mar 24, 2026 | clinicaltrials |
| NCT07482319 | A Clinical Study GK01 Injection in Subjects With Advanced Malignant Solid Tumors | not yet recruiting | Phase 1 | 15 | Beijing Geekgene Technology Co., LTDINDUSTRY | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07192315 | Predicting Reactions and Effects of Drugs Immunotherapy and Complications Through Oncosafety (PREDICTO Clinical Study)(PREDICTO) | not yet recruiting | N/A | 160 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT07459920 | Cannabis extrAct in Oncology Patients for the Treatment of TUmor Related Symptom Burden(CAPTURE) | not yet recruiting | Phase 2 | 156 | National Cancer Institute, NaplesOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT07462442 | Study of QLS5308 in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 192 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Mar 10, 2026 | clinicaltrials |
| NCT07453394 | QLS5132 Combination Therapy in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 626 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Mar 6, 2026 | clinicaltrials |
| NCT07450352 | SEED-CRYO: Sequential 125I Seed Implantation Followed by Cryoablation vs Single-Modality Local Therapy in Unresectable Solid Tumors | not yet recruiting | Phase 2 | 150 | Li MinOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07438093 | Safety, Tolerability, and Preliminary Efficacy of Peginterferon α-2b in Combination With an Anti-PD-1 Antibody in Patients With Advanced or Metastatic Malignant Solid Tumors | not yet recruiting | N/A | 60 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07434609 | Evaluation of T320, an Anti-Tissue Factor Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 150 | Nanolattix Biotechnology Co., Ltd.INDUSTRY | 0 | Feb 25, 2026 | clinicaltrials |
| NCT07389239 | A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies. | not yet recruiting | Phase 1 / Phase 2 | 24 | University of ChicagoOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT07423117 | A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy | not yet recruiting | Phase 1 | 102 | IntoCell, IncINDUSTRY | 0 | Feb 20, 2026 | clinicaltrials |
| NCT07417501 | Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 Amplification | not yet recruiting | Phase 2 | 60 | Tongji HospitalOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07396090 | Study of KRAS-Specific Vaccine in Patients With KRAS-Mutated Solid Tumors | not yet recruiting | N/A | 13 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Feb 9, 2026 | clinicaltrials |
| NCT07391644 | A Study of JSKN027 in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 250 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Feb 6, 2026 | clinicaltrials |
| NCT07385950 | Evaluation of the Diagnostic Efficacy of a αvβ6/FAP-Targeting Heterodimeric Probe in Patients With Malignant Solid Tumors | not yet recruiting | — | 100 | Zhongnan HospitalOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT06772090 | Probiotic Supplementation During Cytotoxic Chemotherapy for Solid Tumor Malignancies | not yet recruiting | N/A | 40 | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Feb 3, 2026 | clinicaltrials |
| NCT07375446 | Traditional Chinese Medicine Hand-Foot Soak for Chemotherapy-Induced Peripheral Neuropathy and Hand-Foot Syndrome | not yet recruiting | — | 300 | Peking University Third HospitalOTHER | 0 | Jan 29, 2026 | clinicaltrials |
| NCT07363369 | Exploratory Clinical Study of FAP mRNA Vaccine in Patients With Advanced Malignant Solid Tumors | not yet recruiting | Phase 1 | 10 | West China HospitalOTHER | 0 | Jan 23, 2026 | clinicaltrials |
| NCT07358884 | First in Human Study of QLS5316 in Solid Tumors | not yet recruiting | Phase 1 | 300 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Jan 22, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 8, 2026source: clinicaltrials